1. Ashihara H. Plant biochemistry: Trigonelline biosynthesis in Coffea arabica and Coffea canephora. Coffee Health Dis Prev. 2015; 19-28. [DOI:10.1016/B978-0-12-409517-5.00003-6] [
DOI:10.1016/B978-0-12-409517-5.00003-6]
2. Barbalho SM, Bosso H, Salzedas-Pescinini LM, de Alvares Goulart R. Green tea: A possibility in the therapeutic approach of inflammatory bowel diseases? Green tea and inflammatory bowel diseases. Complement Ther Med. 2019; 43:148-53. [DOI:10.1016/j.ctim.2019.01.015] [PMID] [
DOI:10.1016/j.ctim.2019.01.015]
3. Arnaud M. Products of metabolism of caffeine. In: Dews PB, editor. Caffeine. Berlin: Springer; 1984. [DOI:10.1007/978-3-642-69823-1_1] [
DOI:10.1007/978-3-642-69823-1_1]
4. Azam S, Hadi N, Khan NU, Hadi SM. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit. 2003; 9(9):BR325-30. [PMID]
5. Motegi T, Katayama M, Uzuka Y, Okamura Y. Evaluation of anticancer effects and enhanced doxorubicin cytotoxicity of xanthine derivatives using canine hemangiosarcoma cell lines. Res Vet Sci. 2013; 95(2):600-5. [DOI:10.1016/j.rvsc.2013.06.011] [PMID] [
DOI:10.1016/j.rvsc.2013.06.011]
6. Suravajhala R, Poddar R, Nallapeta S, Ullah S. Xanthine derivatives: A molecular modeling perspective. In: Kavi Kishor PB, Bandopadhyay R, Suravajhala P, editors. Agricultural bioinformatics. Berlin: Springer; 2014. [DOI:10.1007/978-81-322-1880-7_17] [
DOI:10.1007/978-81-322-1880-7_17]
7. Georgieva M, Kondeva-Burdina M, Mitkov J, Tzankova V, Momekov G, Zlatkov A. Determination of the antiproliferative activity of new theobromine derivatives and evaluation of their in vitro hepatotoxic effects. Anticancer Agents Med Chem. 2016; 16(7):925-32. [DOI:10.2174/1871520616666151116122633] [PMID] [
DOI:10.2174/1871520616666151116122633]
8. Daly JW. Caffeine analogs: Biomedical impact. Cell Mol Life Sci. 2007; 64(16):2153-69. [DOI:10.1007/s00018-007-7051-9] [PMID] [
DOI:10.1007/s00018-007-7051-9]
9. Duan L, Yang J, Slaughter MM. Caffeine inhibition of ionotropic glycine receptors. J Physiol. 2009; 587(Pt 16):4063-75. [DOI:10.1113/jphysiol.2009.174797] [PMID] [PMCID] [
DOI:10.1113/jphysiol.2009.174797]
10. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999; 51(1):83-133. [link]
11. Head CA, Jurenka JS. Inflammatory bowel disease part I: Ulcerative colitis-pathophysiology and conventional and alternative treatment options. Alternat Med Rev. 2003; 8(3):247-83. [link]
12. Gassull MA. Review article: The role of nutrition in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 20(Suppl 4):79-83. [DOI:10.1111/j.1365-2036.2004.02050.x] [PMID] [
DOI:10.1111/j.1365-2036.2004.02050.x]
13. Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: From pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016; 13(11):654-64. [DOI:10.1038/nrgastro.2016.116] [PMID] [
DOI:10.1038/nrgastro.2016.116]
14. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004; 50(2):81-92. [DOI:10.1016/j.vascn.2003.12.002] [PMID] [
DOI:10.1016/j.vascn.2003.12.002]
15. Kumar V, Abbas AK, Aster JC. Robbins and cotran pathologic basis of disease, professional edition e-book. Amsterdam: Elsevier Health Sciences; 2020. [Link]
16. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2004; 99(7):1371-85. [DOI:10.1111/j.1572-0241.2004.40036.x] [PMID] [
DOI:10.1111/j.1572-0241.2004.40036.x]
17. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut. 2006; 55(6):749-53.[DOI:10.1136/gut.2005.082909] [PMID] [PMCID] [
DOI:10.1136/gut.2005.082909]
18. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998; 43(1):29-32. [DOI:10.1136/gut.43.1.29] [PMID] [PMCID] [
DOI:10.1136/gut.43.1.29]
19. Pulli B, Ali M, Forghani R, Schob S, Hsieh KL, Wojtkiewicz G, et al. Measuring myeloperoxidase activity in biological samples. Plos One. 2013; 8(7):e67976. [DOI:10.1371/journal.pone.0067976] [PMID] [PMCID] [
DOI:10.1371/journal.pone.0067976]
20. Froushani SM, Galeh HE. New insight into the immunomodulatory mechanisms of Tretinoin in NMRI mice. Iran J Basic Med Sci. 2014; 17(9):632-7. [PMID] [PMCID]
21. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2):351-8. [DOI:10.1016/0003-2697(79)90738-3] [PMID] [
DOI:10.1016/0003-2697(79)90738-3]
22. Barnes PJ. The problem of cough and development of novel antitussives. Pulm Pharmacol Ther. 2007; 20(4):416-22. [DOI:10.1016/j.pupt.2006.11.001] [PMID] [
DOI:10.1016/j.pupt.2006.11.001]
23. Lee HJ, Lee KW, Kang KS, Kim DY, Park HH, Lee MJ, et al. Theobromine with an anti-carcinogenic activity [Internet]. 2004 [Updated 2023 August6 27]. Available from: [Link] [
DOI:10.1248/bpb.27.1883]
24. Iaia N, Rossin D, Sottero B, Venezia I, Poli G, Biasi F. Efficacy of theobromine in preventing intestinal CaCo-2 cell damage induced by oxysterols. Arch Biochem Biophys. 2020; 694:108591. [DOI:10.1016/j.abb.2020.108591] [PMID] [
DOI:10.1016/j.abb.2020.108591]
25. Halliwell B. Antioxidant characterization. Methodology and mechanism. Biochem Pharmacol. 1995; 49(10):1341-8. [DOI:10.1016/0006-2952(95)00088-H] [PMID] [
DOI:10.1016/0006-2952(95)00088-H]
26. Macaigne G, Lahmek P, Locher C, Lesgourgues B, Costes L, Nicolas MP, et al. Microscopic colitis or functional bowel disease with diarrhea: A French prospective multicenter study. Am J Gastroenterol. 2014; 109(9):1461-70. [DOI:10.1038/ajg.2014.182] [PMID] [
DOI:10.1038/ajg.2014.182]
27. Ansley DM, Wang B. Oxidative stress and myocardial injury in the diabetic heart. J Pathol. 2013; 229(2):232-41. [DOI:10.1002/path.4113] [PMID] [PMCID] [
DOI:10.1002/path.4113]
28. Lodovici M, Giovannelli L, Pitozzi V, Bigagli E, Bardini G, Rotella CM. Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control. Mutat Res. 2008; 638(1-2):98-102. [DOI:10.1016/j.mrfmmm.2007.09.002] [PMID] [
DOI:10.1016/j.mrfmmm.2007.09.002]
29. Salamatian M, Mohammadi V, Abtahi Froushani SM. [Ameliorative effects of aqueous cinnamon extract on ulcerative colitis in rats (Persian)]. Physiol Pharmacol. 2019; 23(2):140-9. [Link]
30. Esmaeilnejad B, Abtahi Froushani SM, Tehrani AA, Esmaeili Gouvarchin Ghaleh H, Moshrefzadeh F. [The effects of fasciola hepatica on acetic acid induced ulcerative colitis in rat model (Persian)]. J Fasa Univ Med Sci. 2018; 8(4):1136-45. [Link]
31. Varshosaz J, Minaiyan M, Mollanoori E. [Anti-inflammatory effects of ketotifen in acetic acid-induced ulcerative colitis in rats (Persian)]. J Isfahan Med Sch. 2013; 31(226):138-49. [Link]
32. Tahmasebi P, Abtahi Froushani SM, Afzale Ahangaran N. Thymol has beneficial effects on the experimental model of ulcerative colitis. Avicenna J Phytomed. 2019; 9(6):538-50.[DOI:10.22038/AJP.2019.13383] [PMID] [PMCID]
33. Abtahi Froushani SM, Abbasi A. [Conditioned medium of mesenchymal stem cells pulsed with theobromine can instruct anti-inflammatory neutrophils (Persian)]. Zahedan J Res Med Sci. 2020; 22(2):e86967. [DOI:10.5812/zjrms.86967] [
DOI:10.5812/zjrms.86967]
34. Abtahi Froushani SM, Mashouri S. [The beneficial effects of hypiran in Ameliorating Rat Model of Ulcerative Colitis (Persian)]. Zahedan J Res Med Sci. 2018; 20(1):e58919. [DOI:10.5812/zjrms.58919] [
DOI:10.5812/zjrms.58919]